83671-73-2

Basic information

• Product Name: 2-benzylthio-3-phenyl-4-oxo-3,4-dihydroquinazoline
• Synonyms: 2-benzylthio-3-phenyl-4-oxo-3,4-dihydroquinazoline
• CAS NO: 83671-73-2
• Molecular Weight: 344.437
• Mol File: 83671-73-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-benzylthio-3-phenyl-4-oxo-3,4-dihydroquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-benzylthio-3-phenyl-4-oxo-3,4-dihydroquinazoline(83671-73-2)
• EPA Substance Registry System: 2-benzylthio-3-phenyl-4-oxo-3,4-dihydroquinazoline(83671-73-2)

Safety Data

• Hazardous Substances Data: 83671-73-2(Hazardous Substances Data)

Upstream product

• 13037-60-0 1-bromo-2-isothiocyanatobenzene 
• 100-39-0 benzyl bromide 
• 103-71-9 phenyl isocyanate 
• 118-92-3 anthranilic acid 
• 18741-24-7 3-phenyl-2-thioxo-2,3-dihydro-1H-quinazolin-4-one 
• 103-72-0 phenyl isothiocyanate 

Relevant articles and documents

S-SUBSTITUTED QUINAZOLINES AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF DISEASES MEDIATED BY PDE7

The present invention relates to a family of S-substituted quinazoline derivatives that inhibitors of the enzyme phosphodiesterase 7 (PDE7), useful for the treatment or prevention of diseases mediated by said enzyme, especially inflammatory, neurodegenera

Synthesis of thioether derivatives of quinazoline-4-one-2-thione and evaluation of their antiplatelet aggregation activity

A series of 2-(arylmethylthio)-3-phenylquinazolin-4-one derivatives have been synthesized and their antiplatelet aggregation activities were assessed against ADP and arachidonic acid-induced platelet aggregation in human plasma. Among the tested thioethers, derivative 2, 3, 5 and 16 were the most potent compounds with satisfactory IC50 for inhibition of platelet aggregation induced by ADP. Analysis of global physicochemical parameters shows some correlations between activities and molecular volume and also surface area of the studied derivatives.

4(3H)-quinazolinone derivatives and pharmaceutical compositions

4(3H)-Quinazolinone derivatives of formula (I) are provided. STR1 wherein R1 is a hydrogen atom, a C1 -C6 alkyl group, an aryl group, a substituted aryl group, or an aralkyl group; R2 is a C1 -C6 alkylamino group, a phenyl group, a substituted phenyl group, or a 5- or 6-membered heterocyclic group containing one or more N, O or S as a hetero atom or atoms, said heterocyclic group optionally being substituted or fused with a benzene ring; n is 1 or 2; or R2 represents a geranyl group or a dipyridylmethyl group together with the group --(CH2)n --; and X is a hydrogen atom, a C1 -C6 alkyl group or a halogen atom, and pharmaceutically acceptable acid addition salts thereof. They are useful as antiulcer agents.